- Home
- DERM vs KPTI Comparison
DERM vs KPTI Comparison
Compare DERM & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DERM | KPTI |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.9M | 194.8M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | DERM | KPTI |
|---|---|---|
| Price | $7.11 | $9.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $12.67 | ★ $16.00 |
| AVG Volume (30 Days) | 338.9K | ★ 483.9K |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.72 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $61,858,000.00 | ★ $146,067,000.00 |
| Revenue This Year | $39.72 | N/A |
| Revenue Next Year | $63.24 | $22.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.20 | 0.57 |
| 52 Week Low | $4.31 | $3.65 |
| 52 Week High | $9.56 | $10.99 |
Technical Indicators
Market Signals| Indicator | DERM | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 63.54 | 54.01 |
| Support Level | $7.00 | $8.45 |
| Resistance Level | $7.69 | $10.22 |
| Average True Range (ATR) | 0.44 | 0.73 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 86.21 | 47.94 |
Price Performance
Historical ComparisonAbout DERM Journey Medical Corporation
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).